Holen Sie sich die Stockscreener-App
5.24
1.04%
-0.055
Schlusskurs vom Vortag:
$5.295
Offen:
$5.4
24-Stunden-Volumen:
2,994
Relative Volume:
0.25
Marktkapitalisierung:
$186.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.50M
KGV:
-6.8052
EPS:
-0.77
Netto-Cashflow:
$-30.10M
1W Leistung:
-0.76%
1M Leistung:
+0.96%
6M Leistung:
+43.56%
1J Leistung:
+96.25%
1-Tages-Spanne:
$5.20
$5.40
1-Wochen-Bereich:
$5.20
$5.46
52-Wochen-Spanne:
$2.20
$6.1999
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.20 | 190.59M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.26 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.18 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.86 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.34 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.73 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Evaluating Eupraxia Pharmaceuticals Inc. with trendline analysis2025 Volatility Report & Free Expert Verified Stock Movement Alerts - Newser
Eupraxia Pharmaceuticals Inc. Consolidation Zone May Signal Accumulation2025 Winners & Losers & Accurate Entry/Exit Alerts - thegnnews.com
Eupraxia: HC Wainwright raises Buy to $12, PT unchanged. - AInvest
Eupraxia Pharmaceuticals Inc. stock outlook for YEARTrade Entry Report & Long-Term Investment Growth Plans - Newser
Is Eupraxia Pharmaceuticals Inc. stock a growth or value playWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - Newser
Can Eupraxia Pharmaceuticals Inc. hit a new high this monthPortfolio Profit Report & Short-Term Trading Opportunity Alerts - Newser
Eupraxia Pharmaceuticals Inc. stock retracement – recovery analysis2025 Dividend Review & Community Consensus Trade Alerts - Newser
How to recover losses in Eupraxia Pharmaceuticals Inc. stockIPO Watch & Technical Entry and Exit Tips - Newser
Heatmap analysis for Eupraxia Pharmaceuticals Inc. and competitorsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - Newser
Eupraxia Pharmaceuticals Inc. stock trend outlook and recovery pathQuarterly Portfolio Report & Technical Confirmation Alerts - Newser
Eupraxia Pharmaceuticals Advances EoE Treatment Trials Amid Financial Challenges - MSN
How to use Fibonacci retracement on Eupraxia Pharmaceuticals Inc.Quarterly Trade Summary & Daily Entry Point Alerts - Newser
Momentum divergence signals in Eupraxia Pharmaceuticals Inc. chart2025 Momentum Check & Expert Curated Trade Ideas - Newser
Is Eupraxia Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Alerts - Newser
Can trapped investors hope for a rebound in Eupraxia Pharmaceuticals Inc.Quarterly Earnings Report & Technical Entry and Exit Alerts - Newser
Is Eupraxia Pharmaceuticals Inc. the Top Chart Pick This WeekPrice Action & AI Driven Price Predictions - 선데이타임즈
What makes Eupraxia Pharmaceuticals Inc. stock price move sharply2025 Year in Review & Fast Moving Stock Watchlists - beatles.ru
Published on: 2025-08-19 05:01:26 - Newser
What data driven models say about Eupraxia Pharmaceuticals Inc.’s futureEarnings Beat & Low Drawdown Investment Strategies - Newser
Eupraxia Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Decliners & Weekly High Potential Stock Alerts - Newser
EPRX FY2025 EPS Forecast Lowered by Cantor Fitzgerald - Defense World
Signal strength of Eupraxia Pharmaceuticals Inc. stock in tech scanners2025 Volatility Report & AI Powered Trade Plan Recommendations - Newser
What’s the recovery path for long term holders of Eupraxia Pharmaceuticals Inc.Market Risk Analysis & Short-Term High Return Ideas - Newser
RSI Suggests Rebound May Be Near in Eupraxia Pharmaceuticals Inc.2025 Key Highlights & Reliable Trade Execution Plans - sundaytimes.kr
Published on: 2025-08-17 03:19:09 - Newser
Analyzing recovery setups for Eupraxia Pharmaceuticals Inc. investorsWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
Using R and stats models for Eupraxia Pharmaceuticals Inc. forecastingJuly 2025 Snapshot & Daily Risk Controlled Trade Plans - Newser
Best data tools to analyze Eupraxia Pharmaceuticals Inc. stockTrade Risk Assessment & Reliable Breakout Stock Forecasts - Newser
Is Eupraxia Pharmaceuticals Inc. forming a reversal patternEarnings Recap Report & Long-Term Safe Investment Plans - Newser
HC Wainwright Issues Pessimistic Forecast for EPRX Earnings - Defense World
Multi asset correlation models including Eupraxia Pharmaceuticals Inc.2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Tools to monitor Eupraxia Pharmaceuticals Inc. recovery probabilityInsider Buying & Weekly Stock Performance Updates - Newser
Institutional scanner results for Eupraxia Pharmaceuticals Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Volume spikes in Eupraxia Pharmaceuticals Inc. stock – what they meanJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
What high frequency data says about Eupraxia Pharmaceuticals Inc.Portfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
Is Eupraxia Pharmaceuticals a buy? - Cantech Letter
Trend Reversal Possible in Eupraxia Pharmaceuticals Inc. Charts IndicateJuly 2025 Sector Moves & Stock Market Timing Techniques - 선데이타임즈
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):